Clinical NewsNews

BLOOD TRANSFUSION | Hemanext Begins Rollout of Hemanext ONE® RBC Processing And Storage System In Europe

On July 12, 2022, Hemanext announced a significant milestone in the rollout of its Hemanext ONE® RBC (Red Blood Cell) Processing and Storage System in Europe.

Physicians in Norway have initiated recruitment of chronically transfused patients with haematological malignancies, including myelodysplastic syndrome (MDS), to receive transfusions using RBCs processed and stored with the Hemanext ONE® system.

The Hemanext ONE® system is a new hypoxic storage method, which the company and many researchers and clinicians believe might improve the quality of life for patients that require chronic and high-volume transfusions, including people with thalassaemia and other haemoglobin disorders. Optimizing transfusions is critically important at this time, as societies around the world attempt to preserve and expand the blood supply.

Martin Cannon, Co-Founder, and CEO of Hemanext stated: “After receiving European CE mark certification last year, beginning the treatment of patients in Europe with hypoxically stored RBCs will mark a significant milestone, both for our company and for transfusion patients globally. Our technology has the potential to facilitate efficient treatment of patients in need, and we look forward to continuing to expand our presence into additional European markets over the course of 2022.”

In the EU, the system is CE Marked for the processing and storage of CPD/ PAGGSM Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared and processed with the Hemanext ONE® system within 24 hours of collection. The Hemanext ONE® system limits the O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2 /CO2 Reduced may be stored for up to 42 days at 1-6°C. Hemanext ONE® is used for volumes no greater than 350 ml of LR RBC.1. Blood centers can utilize the device to convert a unit of conventional, leukoreduced RBCs into a transfusion-ready unit of RBCs that, based on pre-clinical data, offloads oxygen better than conventional blood and reduces progressive damage that occurs naturally during storage.

In the fall of 2022, the company anticipates announcing study enrollment for thalassaemia patients in Italy and sickle cell disease (SCD) patients in Switzerland.

As a partner of Hemanext and being committed to promote the safety and effectiveness of the clinical management of thalassaemia, TIF welcomes this highly promising development and eagerly awaits its deployment to the thalassaemia patient communities.

Read the company’s Full Press Release HERE.

Back to top button